Engineered nanovesicles combined with chemotherapy for enhancing tumor immunotherapy(PDF)
《中国医学物理学杂志》[ISSN:1005-202X/CN:44-1351/R]
- Issue:
- 2023年第4期
- Page:
- 480-486
- Research Field:
- 生物材料与力学
- Publishing date:
Info
- Title:
- Engineered nanovesicles combined with chemotherapy for enhancing tumor immunotherapy
- Author(s):
- GAO Kefan; ZHAO Xingzhong
- School of Physics and Technology, Wuhan University, Wuhan 430072, China
- Keywords:
- Keywords: engineered nanovesicle doxorubicin immunotherapy synergistic treatment
- PACS:
- R318
- DOI:
- DOI:10.3969/j.issn.1005-202X.2023.04.014
- Abstract:
- Objective To combine immunotherapy with chemotherapy for improving the therapeutic effect, and providing more insights for the development of safe and effective tumor immunotherapy strategies. Methods The engineered nanovesicles were used in the study. The PD-1 receptors expressed on the vesicle membrane targeted PD-L1 on the surface of tumor cells and enhanced the anti-tumor response by disrupting the PD-1/PD-L1 immunosuppressive pathway. Meanwhile, vesicles-encapsulated chemotherapy drug doxorubicin (DOX) entered the tumor nucleus, inhibited the synthesis of DNA and RNA, and induced tumor cell death. Results Experiments confirmed that the prepared PD1-DOX had good stability and high safety, and could accurately target the tumor site. DOX worked at the nucleus to effectively kill tumors. Conclusion This is the first time to combine PD-1 immune checkpoint inhibition with DOX. Because of characteristics of high safety and long circulation, the PD-1 vesicles are taken as the carrier for encapsulating DOX. The prepared material can effectively target and treat tumor cells and achieve effective tumor clearance.
Last Update: 2023-04-25